SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-009818
Filing Date
2021-08-02
Accepted
2021-08-02 16:29:53
Documents
68
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q crvs-20210630x10q.htm   iXBRL 10-Q 1858049
2 EX-31.1 crvs-20210630xex31d1.htm EX-31.1 11895
3 EX-31.2 crvs-20210630xex31d2.htm EX-31.2 11833
4 EX-32.1 crvs-20210630xex32d1.htm EX-32.1 11807
  Complete submission text file 0001558370-21-009818.txt   6653141

Data Files

Seq Description Document Type Size
5 EX-101.SCH crvs-20210630.xsd EX-101.SCH 41535
6 EX-101.CAL crvs-20210630_cal.xml EX-101.CAL 48927
7 EX-101.DEF crvs-20210630_def.xml EX-101.DEF 142384
8 EX-101.LAB crvs-20210630_lab.xml EX-101.LAB 390835
9 EX-101.PRE crvs-20210630_pre.xml EX-101.PRE 281174
10 EXTRACTED XBRL INSTANCE DOCUMENT crvs-20210630x10q_htm.xml XML 1170203
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

IRS No.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37719 | Film No.: 211136393
SIC: 2834 Pharmaceutical Preparations